Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study
Archives of Women's Mental Health · 2025-06 · 28 (3) · 541-550
DOI: 10.1007/s00737-024-01513-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Women's Mental Health, online erschienen am 16.09.2024. Verfasst von Sarah Glynne und 4 weiteren Autor:innen. Beteiligte Einrichtung: Newson Health Menopause and Wellbeing Centre, Church Street, Stratford-Upon-Avon, Warwickshire, CV37 6HB, UK. sarah.glynne@newsonhealth.co.uk. Hauptthemen laut MEDLINE: Testosterone, Postmenopause, Affect, Cognition. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: The purpose of this study was to assess the impact of testosterone therapy on mood and cognitive symptoms in perimenopausal and postmenopausal women. METHODS: A retrospective cohort study undertaken in a UK specialist menopause clinic. 510 women using hormone replacement therapy (HRT) with persistent low libido, cognitive and negative mood symptoms were treated with testosterone cream or gel for 4 months. A modified version of the Greene Climacteric Scale was used to measure self-reported symptom frequency and severity at baseline and 4 months after initiating treatment. RESULTS: All nine cognitive and mood symptoms significantly improved across the study period. Mood improved more than cognition (47% of women reported an improvement in mood vs. 39% reported an improvement in cognition; 34% vs. 22% decrease in mean symptom scores, respectively). Regarding libido, 52% of women reported an improvement; mean symptom score decreased by 33%. CONCLUSION: Transdermal testosterone therapy for 4 months was associated with significant improvements in mood and cognition. Further research including randomised clinical trials are needed to establish the long-term efficacy and safety of testosterone for the treatment of menopausal cognitive and psychological symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Newson Health Menopause and Wellbeing Centre, Church Street, Stratford-Upon-Avon, Warwickshire, CV37 6HB, UK. sarah.glynne@newsonhealth.co.uk.
- Newson Health Menopause and Wellbeing Centre, Church Street, Stratford-Upon-Avon, Warwickshire, CV37 6HB, UK.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
- EGA Institute for Women's Health, Faculty of Population Health Sciences, University College London, London, UK.
ORCID-Profile: Sarah Glynne, Ahmed M Kamel, Dan Reisel, Louise Newson
Zitieren
APA
Glynne, S., Kamal, A., Kamel, A. M., Reisel, D., & Newson, L. (2025). Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Archives of Women's Mental Health, 28(3), 541-550. https://doi.org/10.1007/s00737-024-01513-6
Vancouver
Glynne S, Kamal A, Kamel AM, Reisel D, Newson L. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Archives of Women's Mental Health. 2025;28(3):541-550. doi:10.1007/s00737-024-01513-6
BibTeX
@article{Glynne2025,
author = {Glynne, Sarah and Kamal, Aini and Kamel, Ahmed M and Reisel, Dan and Newson, Louise},
title = {Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study},
journal = {Archives of Women's Mental Health},
year = {2025},
volume = {28},
number = {3},
pages = {541--550},
doi = {10.1007/s00737-024-01513-6}
}
EUVIMED